← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeOne Medicines USA

FDA approvalNew dosing regimenEsophageal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 400 mg IV every six weeks as monotherapy in adults with unresectable or metastatic ESCC after systemic chemotherapy without a PD-1 or PD-L1 inhibitor.

LAMPGEN ANALYSIS

Why it matters

A six-week interval adds a less frequent option for the existing post-chemotherapy monotherapy indication.

What research teams should watch

Review how to continue toxicity and disease monitoring between less frequent infusion visits.

PRIMARY RECORDS

Sources